The P/S multiple is heavily distorted by the lumpy, non-recurring nature of milestone-based revenue, which makes traditional valuation metrics unreliable for assessing intrinsic value. Investors should monitor whether this valuation gap persists as the company approaches critical clinical milestones, as the current pricing suggests a high probability of further equity dilution.

While the 97% gross margin is technically high, it is a byproduct of a pre-commercial business model that has yet to incur significant manufacturing or distribution costs. This suggests that future profitability will likely face further pressure as the company transitions toward commercialization and incurs the associated operational expenses.

The inability to generate positive returns on capital is a direct consequence of the high R&D burn rate relative to the limited revenue generated from licensing activities. This trend warrants further investigation into whether the company's pipeline can eventually achieve the scale necessary to reverse this persistent capital decay.

The rapid depletion of cash reserves relative to quarterly operating losses implies that the company may face an imminent need for external financing. Investors should monitor the cash runway closely, as the current liquidity profile appears insufficient to support the firm's long-term clinical development objectives without significant capital infusion.